Norges Bank’s Rubius Therapeutics, Inc RUBY Stock Holding History

Norges Bank’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-174,519	Closed	-$962K	–	2204
2022 Q1	$962K	Hold	174,519	–	–	﹤0.01%	2057
2021 Q4	$1.69M	Hold	174,519	–	–	﹤0.01%	2052
2021 Q3	$3.12M	Hold	174,519	–	–	﹤0.01%	1990
2021 Q2	$4.26M	Sell	174,519 -205,481	-54%	-$5.14M	﹤0.01%	1928
2021 Q1	$10.1M	Sell	380,000 -70,000	-16%	-$1.02M	﹤0.01%	1786
2020 Q4	$3.42M	Hold	450,000	–	–	﹤0.01%	1910
2020 Q3	$2.25M	Hold	450,000	–	–	﹤0.01%	1958
2020 Q2	$2.69M	Hold	450,000	–	–	﹤0.01%	1934
2020 Q1	$2M	Hold	450,000	–	–	﹤0.01%	1924
2019 Q4	$4.28M	Hold	450,000	–	–	﹤0.01%	1922
2019 Q3	$3.53M	Hold	450,000	–	–	﹤0.01%	1947
2019 Q2	$7.08M	Hold	450,000	–	–	﹤0.01%	1886
2019 Q1	$8.14M	Hold	450,000	–	–	﹤0.01%	1862
2018 Q4	$7.24M	Hold	450,000	–	–	﹤0.01%	1838
2018 Q3	$10.8M	Buy	+450,000	New	+$10.3M	﹤0.01%	1799

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank's RUBY Position: Q2 2022 in Review

Norges Bank sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 174,519 shares — an estimated $962K sold.

Norges Bank first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $10.8M in Q3 2018. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Norges Bank reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 174,519 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $962K.
Norges Bank first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
Norges Bank's Rubius Therapeutics, Inc position peaked at $10.8M in Q3 2018.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.